Current influenza A virus (IAV) vaccines stimulate antibody responses that are directed against variable regions of the virus, and are therefore ineffective against divergent strains. As CD8 + T cells target the highly conserved, internal IAV proteins, they have the potential to increase heterosubtypic immunity. Early T-cell priming events influence lasting memory, which is required for long-term protection. However, the early responding, IAV-specific cells are difficult to monitor because of their low frequencies. Here, we tracked the dissemination of endogenous IAV-specific CD8 + T cells during the initial phases of the immune response following IAV infection. We exposed a significant population of recently activated, CD25 + CD43 + IAV-specific T cells that were not detected by tetramer staining. By tracking this population, we found that initial T-cell priming occurred in the mediastinal lymph nodes, which gave rise to the most expansive IAV-specific CD8 + T-cell population. Subsequently, IAV-specific CD8 + T cells dispersed to the bronchoalveolar lavage and blood, followed by spleen and liver, and finally to the lung. These data provide important insight into the priming and tissue dispersion of an endogenous CD8 + T-cell response. Importantly, the CD25 + CD43 + phenotype identifies an inclusive population of early responding CD8 + T cells, which may provide insight into TCR repertoire selection and expansion. A better understanding of this response is critical for designing improved vaccines that target CD8 + T cells.
INTRODUCTION
Current influenza A virus (IAV) vaccines are only effective against IAV subtypes included in the vaccine, and therefore do not protect against slightly divergent or novel IAV strains. Thus, developing a successful universal IAV vaccine that induces immunity to regions of IAV that are conserved between different subtypes is of utmost importance. An effective universal vaccine is likely to require both humoral and cellular responses. While the major IAV epitopes targeted by B cells vary between IAV subtypes, CD8 + T cells recognize epitopes from internal IAV proteins that are primarily conserved across multiple subtypes. 1 Thus, vaccines optimizing CD8 + T cell-mediated immunity may enhance protection against novel seasonal and pandemic IAVs.
Mouse models of IAV pneumonia provide a welldeveloped experimental system for analyzing CD8 + T cellmediated immunity. In C57BL/6 (H2 b ) mice, the CD8 T-cell activation, expansion, and memory generation during an in vivo infection is critical for comprehending these immunodominance patterns and developing improved IAV vaccines.
Following intranasal IAV infection, na€ ıve IAV-specific CD8 + T cells first encounter the viral peptides presented by MHCI complexes on dendritic cells in the mediastinal lymph nodes (MLN), which drain the respiratory tract. TCR diversity ensures that the individual T cells that comprise the responding repertoire bind peptide-MHCI with variable avidities, with high avidity T cells typically proliferating more extensively following antigen encounter. [3] [4] [5] Such recognition of their cognate peptide-MHCI induces CD8 + T-cell activation, proliferation, and subsequent migration to the lung where effector CTLs directly interact with the infected airway epithelium to lyse infected target cells and limit viral spread. The spleen has also been described as a major priming site for CD8 + T cells during IAV infection. 6 Given that the priming environment impacts differentiation of memory CD8 + T cells, it is important to discern the relative contribution of lymph node versus splenic priming.
Many factors influence the magnitude of the CD8 + T-cell response following infection. In particular, the cellular environment and the initial priming of na€ ıve CD8 + T cells dictate the efficacy of recall responses, and therefore impact vaccine efficacy. [7] [8] [9] [10] Analysis of the early events of IAV-specific CD8 + T-cell responses has been limited, in part because numbers of virus-specific CD8 + T cells remain low during the initial stages following antigen encounter. To circumvent this limitation, several groups transferred na€ ıve, TCR transgenic T cells into recipients prior to infection to increase the precursor frequency and hence, responding population. 6, 11 While these studies have provided invaluable insights, their interpretation has been confounded by using unnaturally high CD8 + effector T-cell precursor frequencies. 12 Furthermore, use of TCR transgenic mice also perturbs the natural diversity in TCR affinity for the peptide-MHCI complexes, the competition between T cells specific for different viral epitopes, and the timing of antigen exposure and stimulatory microenvironments dictated by antigen presenting cells; all of which impact the immune response. 8, 13, 14 Therefore, it is important to study the immune response in an endogenous model represented by naturally occurring TCR specificities and response kinetics.
Magnetic enrichment of antigen-specific T cells with peptide: MHC tetramers has facilitated isolation of small numbers of endogenous, antigen-specific CD8 + T cells, which has been instrumental in examining the relationship between na€ ıve CD8 + T-cell precursor frequency and the magnitude of the CD8 + T-cell response. [15] [16] [17] Initially, CD8 + T-cell frequencies were identified as a strong determinant of the magnitude of the response. However, it is becoming increasingly evident that multiple factors contribute to CD8 + T-cell expansion. 9, 18, 19 PB1-F2 62 -specific T cells, indicating that precursory frequency is not the sole determinant of the magnitude of the CD8 + T-cell response. 18, 19 Further experiments demonstrated that the capacity of the T cells to proliferate following IAV infection and the avidity of the TCR for antigen also contribute to the magnitude of the CD8 + T-cell response. While isolation of T cells with tetramers allows detection of a small number of cells, this approach relies on pooling cells from multiple lymphoid organs, and therefore cannot be used to track the dispersion of small numbers of antigen-specific T cells to each organ. Furthermore, individual tetramers may only detect a subset of the total pool of antigen-specific T cells. As the environment in which a T cell encounters antigen influences the capacity of that T cell to become a memory or an effector T cell, we wished to characterize the early priming and tissue dispersion of IAV-specific CD8 + T cells during IAV infection. Additionally, we examined whether specific surface markers could be used to identify IAV-specific T cells early in the response. We found that the CD25 + CD43 + CD8 + phenotype provided a more effective measure of IAV-specific CD8 + T-cell frequencies than tetramer analysis during the early events following priming. By tracking the progression of CD25 + CD43 + CD8 + T cells and tetramer-positive T cells, we showed that priming in the MLN gave rise to the most expansive population of IAV-specific CD8 + T cells. At later time points, the bronchoalveolar lavage (BAL) and lung were enriched for effector CD8 + T cells, while the spleen and MLN harbored memory populations. These findings provide insight into the activation and dispersion of endogenous, IAV-specific CD8 + T cells, which is important for developing methods to enhance CD8 + T-cell memory during IAV vaccination.
RESULTS
Tissue specific dissemination kinetics of IAV-specific CD8 + T cells + T cells were first detected 4 days after infection in the MLN, but not in other tissues, with a more defined population appearing in the MLN 1 day later (Figure 1 ). Six days after infection, all epitope-specific cells were detectable in the BAL, lung, liver, spleen, bone marrow, and blood ( Figure 1 ). In general, there was a steady increase in the number of antigen-specific CD8 + T cells in all sites until 8 days after infection when some populations began to decline. The lowest numbers of IAV-specific CD8 + T cells were found in the bone marrow, while the highest numbers were in the lung, followed by spleen. Anderson et al. demonstrated that despite perfusion, the majority of CD8 + T cells derived from the lung were confined to the pulmonary vasculature, rather than the lung parenchyma. 20 Therefore, to distinguish lung-resident, IAV-specific CD8 + T cells from blood-borne cells, we performed in vivo labeling via intravenous injection of anti-CD8a antibody 3 min prior to sacrificing the mice. Recovered cell suspensions were stained with anti-CD8b antibody to distinguish blood derived (CD8a + CD8b + ) cells from lungresident cells (CD8a À   CD8b  + ) . 20 This analysis revealed that approximately two-thirds of the total CD8 + T cells recovered from the lung were in the parenchyma. However, the overall kinetics of expansion of IAV-specific CD8 + T cells in the lung was unaltered by removing bloodborne CD8 + T cells from analysis ( Figure 1 , lung-resident and blood). Overall, the lung parenchyma and spleen harbored the most IAV-specific CD8 + T cells 7 days after infection, but the spleen dominated the response 3 days later.
Analysis of the different TCR specificities showed that the D b PB1-F2 62 -specific CD8 + T cells were the least common throughout the response ( Figure 1a) . The K b PB1 703 -specific CD8 + T cells dominated the initial response in several tissues and remained co-dominant throughout the course of the infection in the BAL and lung, but not at other sites. While the D b PA 22 -specific population was the first to reach the peak of its expansion, the D b NP 366 -specific T cells were "slow starters", and were outnumbered by all other epitopespecific T cells in most organs early in the response, but became more prominent later in the response. Intriguingly, the kinetics of the response to each epitope does not correlate well with predicted estimates of the level or rate of antigen processing and presentation. It is estimated that NP 366 is presented the most rapidly after infection followed by NS2 114 and PB1-F2 62, then PB1 703, and finally PA 224 . 21 Thus, other factors such as the precursor frequency, the cell type presenting the antigen, the duration of antigen presentation, and the location of antigen presentation likely contribute to the immunodominance hierarchies.
To assess the relative proportion of IAV-specific CD8 + T cells at each site, we compared the frequency of tetramer-binding cells within the CD8 + T cell compartment of each organ. The lung, BAL, and liver had the highest frequency of IAV-specific cells within the CD8 + population (Figure 1b) . In contrast, IAV-specific cells accounted for only a small proportion of the CD8 + T cells in the MLN, spleen, bone marrow, and blood. This is likely due to the large numbers of na€ ıve CD8 + T cells in the lymphoid organs. Together, these data show that the hierarchy of CD8 + T cells specific for each epitope varies at different time points and between various tissues, suggesting that the magnitude of each response is not solely determined by the frequency of na€ ıve precursors prior to infection, which is consistent with other reports.
Recently primed IAV-specific CD8
+ T cells express a CD25 + CD43 + phenotype
To identify a set of activation markers associated with IAV-specific CD8 + T cells during the initial phase of the immune response, we assessed the expression of CD25, the active form of CD43, CD69, and CD62L on D Priming in the MLN leads to expansion of the largest population of IAV-specific CD8 + T cells CD25 is transiently expressed immediately following activation, prior to cell division, 23, 24 while the active form of CD43 is maintained on effector cells until progression to a memory phenotype. 25 Therefore, it is likely that during the course of the infection, the CD25 + CD43 26 was injected 52 h after intranasal HKx31 infection and then every 24 h until harvest, as previously described. 27 The initial lag between HKx31 infection and the first Fingolimod injection allowed sufficient time for the migration of APCs from infected tissue to the lymphoid tissue. Cells were harvested from the MLN, BAL, and spleen 5, 6, and 7 days after infection. Fingolimod treatment significantly increased the numbers of D b PA 224 -specific CD8 + T cells in the MLN, while decreasing the numbers in the BAL and spleen, indicating that egress from the MLN was blocked (Figure 3a-c) . The fact that antigen-specific CD8 + T cells failed to accumulate in substantial numbers at other sites when exit from the MLN was blocked, suggests that the majority of the antigen-specific CD8 + T cells in the other organs are derived from the MLN. While priming in the spleen following IAV infection may contribute to the CD8 + T-cell response as reported by others, 6 our data indicate that priming outside of the MLN makes a minor contribution to the overall response. Furthermore, blocking T-cell egress from the MLN resulted in an accumulation of CD25 (Figure 4c ). The number of cells present in these organs at this time was negligible compared to those obtained at later time points as depicted in Figure 1 . Furthermore, the number of CD25 + CD43 + CD8 + T cells present in the spleen, liver, and BAL was similar between na€ ıve mice and infected mice, suggesting that in these organs, there is either a very low level of CD25 + CD43 + CD8 + T cells or background staining contributes to the numbers. In contrast, there was an increase in CD25 + CD43 + CD8 + T cells in the MLN 4 days after infection compared to na€ ıve mice, consistent with responding cells first appearing in the MLN. Together, these data suggest that the CD8 + T cells were primed in the MLN and subsequently migrated to the BAL and blood, followed by the liver and spleen, and finally the lung. (Figure 5c ). This was true for both the subset that bound the four tetramers and the tetramer-negative subset. As the CD25 + tetramer-negative T cells proliferated following IAV infection, it is likely that they are IAV-specific since antigen encounter is required for T cell proliferation. This was even more striking in the MLN CD25 + CD43 14 The TKO virus grows as efficiently as the WT virus in vivo; however, growth of the QKO virus is reduced, although it induces a productive infection.
14 Because of the lack of the dominant CD8 epitopes, the magnitude of the overall CD8 response is reduced following infection with the TKO and QKO viruses compared to the wild-type virus. As expected, the number of tetramer-positive CD8 + T cells was significantly lower in mice infected with the TKO or QKO viruses compared to the wild-type virus ( Figure 6 ). Interestingly, the number of CD25 + CD43 + CD8 + T cells was also significantly reduced following infection with the TKO and QKO viruses compared to the WT virus, showing a correlation between the magnitude of CD25 + CD43 + CD8 + population and the number of CD8 epitopes presented (Figure 6 (n = 6 or 7 mice per group from 1 experiment) *P < 0.05, **P < 0.01 (Mann-Whitney U-test ( Figure 7a ). These data indicate that tetramer binding grossly underestimates the frequency of IAV-specific CD8 + T cells during the early immune response to IAV. Furthermore, comparing frequency of IFN-c-secretors to tetramer-binders for each epitope showed that the D b PA 224 tetramer gave the most accurate measure of epitopespecific CD8 + T-cell frequencies, and the D b NP 366 tetramer was the least accurate. This may reflect the higher avidity of D b PA 224 -specific CD8 + T cells for the corresponding peptide. 13 While the number of CD8 + T cells that bound the pooled tetramers was significantly lower than the total number of CD25 + CD43 + CD8 + T cells, the number of IFN-c secreting cells approximated the number of CD25 + CD43 + CD8 + T cells (Figure 7b ). Prior to Day 5 after infection, the number of IAV-specific cells was low, consistent with their initial arrival in the MLN. These data indicate that the CD25 + CD43 + phenotype more accurately reflects the number of IAV-specific CD8 + T cells than tetramer staining at this early time point. Analysis of the IFN-c secreting cells showed that at Day 5 after infection they had a predominantly CD25 + CD43 + phenotype. By Day 6, the IFN-c secreting cells showed some downregulation of CD25; however, CD43 was maintained (Figure 7c ). This is consistent with the fact that IAVspecific CD8 + 
DISCUSSION
Generating long-lived virus-specific CD8 + T-cell memory is critical to the success of a vaccine strategy eliciting T cell-mediated immunity. Over the last decade, early priming events have been found to be critical determinants in generating these populations. More recently, it has become clear, that the magnitude of the CD8 + T-cell response is also impacted by precursor frequency of a given TCR specificity, the affinity of that TCR for its ligand, the capacity of a cell to proliferate, and competition with T cells of other specificities. 9, 18 Determining the impact of each of these factors on expansion of endogenous TCRs is difficult because of the low number of cells specific for each epitope.
Here, we identified a population of CD8 + T cells with a CD25 + CD43
+ phenotype that were predominantly IAVspecific based on several criteria. First, the CD25 + CD43 + cells that did not bind tetramers made IFN-c following a short in vitro restimulation with cognate peptide. Second, TCR sequences were conserved between the CD25 + CD43 + cells that bound tetramer and the CD25 + CD43 + cells that did not bind tetramer, suggesting that these populations share common TCR specificities. Third, infection with viruses that lack the dominant CD8 epitopes generated fewer tetramer-positive and fewer CD25 + CD43 + T cells, showing a correlation between the number of CD25 + CD43 + and tetramer-positive T cells. Finally, the fact that the CD25 + CD43 + T cells proliferated after infection suggests that these cells are IAV-specific as T cells that are not specific for IAV should not proliferate in the absence of TCR stimulation. Together, these data support the contention that the CD25 + CD43 + phenotype can be used as a marker to track recently activated IAVspecific CD8 + T cells. Using the CD25 + CD43 + phenotypic biomarker, we analyzed the activation and dispersion of IAV-specific CD8 + T cells and found that tetramer staining underestimated the number of IAV-specific T cells during the early phases of the response. Based on the CD25 + CD43 + phenotype, approximately 7-15% of the total CD8 + T-cell population in the MLN, 5 days after primary HKx31 infection, was IAV-specific, which is four to eight times greater than the estimate from tetramer staining. Our study therefore highlights the limitation of using tetramers to quantify early antigen-specific responses, and offers an alternative phenotype to track.
The inability of the IAV-specific CD8 + T cells to bind tetramer early in the response could be due to a number of factors. As na€ ıve T cells can effectively bind tetramers, events associated with activation may hinder tetramer binding. 13 Indeed, several groups showed lack of tetramer binding on antigen-specific T-cell populations following activation. [30] [31] [32] [33] One study reported that antigen-specific T cells fail to bind tetramer following stimulation because of transient CD8 downregulation and altered CD8 glycosylation.
30,31 However, we did not observe decreased CD8 expression on the CD25 + CD43 + T cells that did not bind tetramer. While tetramer binding can be influenced by CD8 staining protocols, 34 in our experiments, tetramer binding was unaltered when anti-CD8 antibody was incubated with or following tetramer binding (data not shown), suggesting that tetramer binding was not limited by competitive or cooperative binding. Another study tracking CD8 + T cells with a transgenic TCR demonstrated that IAV-specific T cells failed to bind tetramer for up to 5 days after IAV infection, although the TCR was only downregulated for 1 day. 35 In this study, the lack of tetramer binding was associated with altered organization of the TCR, such that the cells that bound tetramer displayed tight clustering of the TCR, while the tetramer-negative cells had a more diffuse TCR organization. Moreover, these authors also demonstrated that disruption of the lipid rafts impacts tetramer binding. 32 Thus, it is possible that the clustering of the TCR is required for T cells with a lower affinity for antigen to bind tetramer, and that T-cell activation impacts the ability to cluster the TCR. The decreased TCR clustering could be due to the presence of high levels of antigen, differential glycosylation of surface proteins including CD8, or altered interaction with cytoskeletal proteins. Our data are consistent with this model, as we did not see a difference in overall TCR levels on CD25 + CD43 + T cells that bound tetramer versus the CD25 + CD43 + T cells that did not bind tetramer. Consistent with the previous reports, we found that tetramer-binding efficiency increased after 5 days following infection, with a greater proportion of IAVspecific CD8 + T cells binding tetramer at 7 days after infection compared to the earlier time points. Selective expansion of higher affinity T cells may contribute to this increase in tetramer-binding efficiency over time. While individual TCRs do not undergo affinity maturation, the responding population as a whole demonstrates selective expansion of CD8 + T cells over time. 3 Our data indicate that the CD25 + CD43 + CD8 + T cells that did not bind tetramer were still functional as shown by IFN-c synthesis following in vitro stimulation. This is in contrast to previous reports, which used TCR transgenic T cells and in vitro cell lines, and found decreased tetramer binding concomitant with diminished IFN-c synthesis during the early immune response. 33 We previously reported that tetramer staining parallels IFN-c secretion at later time points in the MLN, lung, liver, and spleen. 36 Interestingly, in this study, we observed significant downregulation of CD8 by nontetramer binding CD25 + CD43 + CD8 + T cells recovered from the lung 10 days after infection, suggesting CD8 downregulation may be more prominent at later time points at the infection site. Xiao et al. 31 demonstrated that CD8 downregulation in their system was due to type 1 interferon signaling. Thus, it is possible that the CD8 downregulation we observed in the lung is due to higher levels of type 1 interferon compared to the other organs.
The Priming in the MLN was identified as the main site for generating IAV-specific CD8 + T cells. Using progression of CD25 and CD43 expression to follow migration, the IAV-specific CD8 + T cells appeared next in the blood and BAL, then spleen and liver, followed by the lung. Similarly, TCR transgenic HSV-1-specific T cells had undergone multiple rounds of division by the time they trafficked to the spleen from the draining LN, with little evidence of antigenic stimulation in the spleen. 39 Our findings are also consistent with mathematical modeling, which predicts that a greater proportion of activated CD8 + T cells migrate from the spleen to the lung, rather than from the MLN directly to the lung. 40 Expression of CD43 is maintained on effector cells, correlating with increased cytolytic capacity, and downregulated on memory cells. 25 In addition, CD43 lo memory cells are 2-5 fold more efficient than CD43 hi cells at mediating the recall response. 41 Interestingly, we found that CD43 was gradually downregulated on IAV-specific T cells in all organs except the BAL, lung, and liver. Accordingly, the BAL, lung, and liver are rich in effector cells, while IAVspecific CD8 + T cells in the MLN and spleen give rise to the memory cells. Expression of CD43 has been associated with increased apoptosis 42 ; therefore, the CD8 + T cells in the BAL and lung would be the most susceptible to apoptosis, as previously reported. 36 This suggests that the lung and BAL are enriched for virus-specific effector CD8 + T cells that are more susceptible to death, while, the spleen serves as a significant source of memory CD8 + T cells. However, some reports indicate that memory cells in the spleen cannot provide long-term protection, therefore increasing the reliance on lung resident memory cells. 43 + phenotype identifies an inclusive population of early responding population of cells, which may provide insights for TCR repertoire selection and expansion. CD8 + T cell-based vaccines remain an unrealized goal, efforts to understand and utilize the early events of an immune response, in particular the trafficking and maintenance of memory CD8 + T cells in the lung, may increase the likelihood of a cell-mediated vaccine coming to fruition. PA 224-233 epitopes. 47, 48 In the TKO viruses, the WT D b PB1-F2 62-70 epitope (LSLRNPILV was changed to LSLRQPILV. 49 In the QKO virus, the WT K b PB1 703-711 epitope (SSYRRVPGI) was changed to SSFRRVPGI, and the WT K b NS2 114-121 epitope (RTFSFQLI) was changed to RTFSAQLI.
METHODS

Animals, viruses and infection
Organ removal, lymphocyte recovery, and Intravascular staining
Mice were killed by CO 2 asphyxiation and lymphocytes were recovered from the MLN, BAL, spleen, liver, lung, and blood as previously described. 36 Femurs and tibias were removed, and the bone marrow was flushed out with 5-10 mL of RP10 medium (RPMI 1640 with 10% FCS). To distinguish lung resident and blood borne CD8 + T cells, mice were given tail vein injections of 3 lg of anti-CD8a-APC (clone 53-6.7 from eBioscience) and sacrificed 3 min later, followed by tissue harvest, as described. 20 Flow cytometric analysis and tetramer staining brefeldin A (Epicenter) and 1 lM of peptide, or without peptide for unstimulated controls. After culture, cells were stained with mAb specific for CD8a (53-6.7), CD25 (PC61), CD43(1B11), and mouse CD16/CD32 then fixed in 1% formaldehyde in PBS for 30 min at room temperature. Following fixation, the cells were resuspended in 0.5% saponin (Sigma) for 10 min, incubated with fluorescently labeled anti-IFN-c (XMG1.2) for 30 min at 4°C, followed by flow cytometric analysis.
BrdU incorporation and detection
Na€ ıve, HKx31-virus infected, and allantoic fluid injected (virus control) mice were given sterile drinking water containing BrdU (Sigma Chemical Co., St Louis, MO) at 0.8 mg mL
À1
, which was changed daily and protected from light exposure. Recovered lymphoid cells were first stained for the expression of surface markers, as described above, then washed twice followed by fixing and permeabilizing with the BD Cytofix/Cytoperm reagents (BD Pharmingen, San Jose, CA, USA). The cells were washed again and incubated with 50 Kunz units of DNase (Sigma) for 10 min at 37°C to expose incorporated BrdU. After further washing in BD Perm/Wash buffer (BD Pharmingen) the cells were incubated with anti-BrdU-FITC in BD Perm/wash Buffer (BD Pharmingen) for 20 min at room temperature.
Isolation of single CD8 + T cells, RT-PCR and sequencing
Single-cell suspensions were stained with tetramer and surface markers as described above. After sorting, plates were stored at À80°C. cDNA synthesis was performed in 5 lL of cDNA reaction mixture 90 min at 37°C, followed by 5 min at 95°C. The Vb8.3 cDNA was amplified by rested PCR, and the purified PCR products were sequenced.
Fingolimod treatment
Fingolimod (FTY720, Cayman Chemical, Ann Arbor, MI, USA) was administered i.p. at 1 mg kg À1 (Cayman Chemical, Ann Arbor, MI, USA). Fingolimod was dissolved in DMSO then diluted 1:25 in PBS and 100 lL was injected 52 h after intranasal HKx31 infection and then every 24 h until harvest.
Statistical analysis
Quantitative differences between two samples were compared with the Mann-Whitney U-test (rank sum). A Kruskal-Wallis test was used, followed by Dunn's post hoc test, when three or more groups were compared. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
